Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms

Jennifer St. Sauver, Steven J. Jacobsen, Debra J. Jacobson, Michaela E. McGree, Cynthia J. Girman, Ajay Nehra, Veronique Lee Roger, Michael M. Lieber

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

OBJECTIVE To determine whether statin use is associated with a decreased risk of developing benign prostatic enlargement (BPE) and lower urinary tract symptoms (LUTS). SUBJECTS AND METHODS We conducted a retrospective, population-based cohort study of 2447 men, 40-79 years of age, residing in Olmsted County, MN, USA, in 1990, and followed these men biennially through 2007. Cox proportional hazard models were used to assess associations between statin use and new onset of moderate/severe LUTS (American Urological Association Symptom Index score >7), a decreased maximum urinary flow rate (<12 mL/s) or BPE (prostate volume >30 mL). RESULTS Statin use was inversely associated with new onset of LUTS (Hazard ratio (HR) 0.39; 95% confidence interval (CI) 0.31-0.49), a decreased maximum flow rate (HR 0.53; 95% CI 0.34-0.82) and BPE (HR 0.40; 95% CI 0.23-0.69) after adjustment for baseline age and body mass index, diabetes, hypertension, coronary heart disease, smoking, alcohol use, activity level and non-steroidal anti-inflammatory use. The longest duration of statin use was associated with the lowest risk of developing each outcome (all tests for trend: P < 0.001). CONCLUSION In this study, statin use was associated with a 6.5- to 7-year delay in the new onset of moderate/severe LUTS or BPE. While men typically take statin medications to prevent coronary heart disease events and related outcomes, these data suggest that men who use statins may also receive urologic benefits.

Original languageEnglish (US)
Pages (from-to)443-450
Number of pages8
JournalBJU International
Volume107
Issue number3
DOIs
StatePublished - Feb 2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lower Urinary Tract Symptoms
Confidence Intervals
Coronary Disease
Proportional Hazards Models
Body Mass Index
Cohort Studies
Anti-Inflammatory Agents
Smoking
Alcohols
Hypertension
Population

Keywords

  • BPH
  • prostate
  • Statins

ASJC Scopus subject areas

  • Urology

Cite this

St. Sauver, J., Jacobsen, S. J., Jacobson, D. J., McGree, M. E., Girman, C. J., Nehra, A., ... Lieber, M. M. (2011). Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU International, 107(3), 443-450. https://doi.org/10.1111/j.1464-410X.2010.09598.x

Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. / St. Sauver, Jennifer; Jacobsen, Steven J.; Jacobson, Debra J.; McGree, Michaela E.; Girman, Cynthia J.; Nehra, Ajay; Roger, Veronique Lee; Lieber, Michael M.

In: BJU International, Vol. 107, No. 3, 02.2011, p. 443-450.

Research output: Contribution to journalArticle

St. Sauver, Jennifer ; Jacobsen, Steven J. ; Jacobson, Debra J. ; McGree, Michaela E. ; Girman, Cynthia J. ; Nehra, Ajay ; Roger, Veronique Lee ; Lieber, Michael M. / Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. In: BJU International. 2011 ; Vol. 107, No. 3. pp. 443-450.
@article{a873672c82804096bd6ed8b4c9e80405,
title = "Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms",
abstract = "OBJECTIVE To determine whether statin use is associated with a decreased risk of developing benign prostatic enlargement (BPE) and lower urinary tract symptoms (LUTS). SUBJECTS AND METHODS We conducted a retrospective, population-based cohort study of 2447 men, 40-79 years of age, residing in Olmsted County, MN, USA, in 1990, and followed these men biennially through 2007. Cox proportional hazard models were used to assess associations between statin use and new onset of moderate/severe LUTS (American Urological Association Symptom Index score >7), a decreased maximum urinary flow rate (<12 mL/s) or BPE (prostate volume >30 mL). RESULTS Statin use was inversely associated with new onset of LUTS (Hazard ratio (HR) 0.39; 95{\%} confidence interval (CI) 0.31-0.49), a decreased maximum flow rate (HR 0.53; 95{\%} CI 0.34-0.82) and BPE (HR 0.40; 95{\%} CI 0.23-0.69) after adjustment for baseline age and body mass index, diabetes, hypertension, coronary heart disease, smoking, alcohol use, activity level and non-steroidal anti-inflammatory use. The longest duration of statin use was associated with the lowest risk of developing each outcome (all tests for trend: P < 0.001). CONCLUSION In this study, statin use was associated with a 6.5- to 7-year delay in the new onset of moderate/severe LUTS or BPE. While men typically take statin medications to prevent coronary heart disease events and related outcomes, these data suggest that men who use statins may also receive urologic benefits.",
keywords = "BPH, prostate, Statins",
author = "{St. Sauver}, Jennifer and Jacobsen, {Steven J.} and Jacobson, {Debra J.} and McGree, {Michaela E.} and Girman, {Cynthia J.} and Ajay Nehra and Roger, {Veronique Lee} and Lieber, {Michael M.}",
year = "2011",
month = "2",
doi = "10.1111/j.1464-410X.2010.09598.x",
language = "English (US)",
volume = "107",
pages = "443--450",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms

AU - St. Sauver, Jennifer

AU - Jacobsen, Steven J.

AU - Jacobson, Debra J.

AU - McGree, Michaela E.

AU - Girman, Cynthia J.

AU - Nehra, Ajay

AU - Roger, Veronique Lee

AU - Lieber, Michael M.

PY - 2011/2

Y1 - 2011/2

N2 - OBJECTIVE To determine whether statin use is associated with a decreased risk of developing benign prostatic enlargement (BPE) and lower urinary tract symptoms (LUTS). SUBJECTS AND METHODS We conducted a retrospective, population-based cohort study of 2447 men, 40-79 years of age, residing in Olmsted County, MN, USA, in 1990, and followed these men biennially through 2007. Cox proportional hazard models were used to assess associations between statin use and new onset of moderate/severe LUTS (American Urological Association Symptom Index score >7), a decreased maximum urinary flow rate (<12 mL/s) or BPE (prostate volume >30 mL). RESULTS Statin use was inversely associated with new onset of LUTS (Hazard ratio (HR) 0.39; 95% confidence interval (CI) 0.31-0.49), a decreased maximum flow rate (HR 0.53; 95% CI 0.34-0.82) and BPE (HR 0.40; 95% CI 0.23-0.69) after adjustment for baseline age and body mass index, diabetes, hypertension, coronary heart disease, smoking, alcohol use, activity level and non-steroidal anti-inflammatory use. The longest duration of statin use was associated with the lowest risk of developing each outcome (all tests for trend: P < 0.001). CONCLUSION In this study, statin use was associated with a 6.5- to 7-year delay in the new onset of moderate/severe LUTS or BPE. While men typically take statin medications to prevent coronary heart disease events and related outcomes, these data suggest that men who use statins may also receive urologic benefits.

AB - OBJECTIVE To determine whether statin use is associated with a decreased risk of developing benign prostatic enlargement (BPE) and lower urinary tract symptoms (LUTS). SUBJECTS AND METHODS We conducted a retrospective, population-based cohort study of 2447 men, 40-79 years of age, residing in Olmsted County, MN, USA, in 1990, and followed these men biennially through 2007. Cox proportional hazard models were used to assess associations between statin use and new onset of moderate/severe LUTS (American Urological Association Symptom Index score >7), a decreased maximum urinary flow rate (<12 mL/s) or BPE (prostate volume >30 mL). RESULTS Statin use was inversely associated with new onset of LUTS (Hazard ratio (HR) 0.39; 95% confidence interval (CI) 0.31-0.49), a decreased maximum flow rate (HR 0.53; 95% CI 0.34-0.82) and BPE (HR 0.40; 95% CI 0.23-0.69) after adjustment for baseline age and body mass index, diabetes, hypertension, coronary heart disease, smoking, alcohol use, activity level and non-steroidal anti-inflammatory use. The longest duration of statin use was associated with the lowest risk of developing each outcome (all tests for trend: P < 0.001). CONCLUSION In this study, statin use was associated with a 6.5- to 7-year delay in the new onset of moderate/severe LUTS or BPE. While men typically take statin medications to prevent coronary heart disease events and related outcomes, these data suggest that men who use statins may also receive urologic benefits.

KW - BPH

KW - prostate

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=79251558136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251558136&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2010.09598.x

DO - 10.1111/j.1464-410X.2010.09598.x

M3 - Article

C2 - 20804476

AN - SCOPUS:79251558136

VL - 107

SP - 443

EP - 450

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -